Timing of HCG Administration in IUI Cycles

Mohamed Ibrahem Eid

Status and phase: Unknown; Phase 4

Conditions: Infertility

Treatments: Drug: HCG

Study type: Interventional

Funder types: Other

Identifiers

NCT02330705

MIE3

Details and patient eligibility

About

Evaluation of the effect of altering the timing of human chorionic gonadotropin (HCG) administration on the clinical pregnancy rate in intrauterine insemination (IUI) cycles.

Full description

Women will be randomly divided into 3 groups; the first group will undergo IUI at the time HCG administration, the second group will undergo IUI 12 hours after HCG administration and the third group will undergo IUI 34-36 hours after HCG administration.

Enrollment: 225 estimated patients

Sex: Female

Ages: 20 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Mild male factor infertility or unexplained infertility.

Exclusion criteria

• Advanced male factor infertility.
• Polycystic ovary syndrome (PCOS) as defined by the Rotterdam criteria.
• Endometriosis.
• Tubal disease.
• Uterine abnormalities or myoma.
• Previous uterine surgery.
• Metabolic or hormonal abnormalities.

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

225 participants in 3 patient groups

Group A

Active Comparator group

Description:

IUI at time of HCG

Treatment:

Drug: HCG

Group B

Active Comparator group

Description:

IUI 12 hours after HCG

Treatment:

Drug: HCG

Group C

Active Comparator group

Description:

IUI 34-36 hours after HCG

Treatment:

Drug: HCG